Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875809 | 0.93 | MAPT (0.36) | MAPTKMT2AMEN1POLBRAB9A | |
| SCHEMBL5875886 | 0.84 | HPGD (0.35) | MAPTKMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL5875754 | 0.83 | RAD52 (0.42) | MAPTKMT2AMEN1POLBRAB9A | |
| SCHEMBL5875891 | 0.78 | GABRA1 (0.36) | MAPTKMT2AMEN1POLBRAB9A | |
| SCHEMBL238448 | 0.77 | ALDH1A1 (0.37) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5875813 | 0.76 | RAD52 (0.41) | MAPTKMT2AMEN1POLBRAB9A | |
| SCHEMBL5875888 | 0.67 | RAD52 (0.40) | MAPTKMT2AMEN1POLBRAB9A | |
| SCHEMBL242600 | 0.67 | ALDH1A1 (0.36) | KMT2AMEN1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4903308 | 0.66 | ALDH1A1 (0.39) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL7225925 | 0.62 | L3MBTL1 (0.51) | MAPTKMT2AMEN1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989387-B2 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040110760-A1 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2004-06-10 | — | — | US | disclosed |
| WO-2004014918-A1 | NITRO AND AMINO SUBSTITUTED TOPOISOMERASE AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110760-A1 | Nitro and amino substituted topoisomerase agents | TOP1, TOP2A, TOP2B | MAPT 4360/4885KMT2A 1207/4885MEN1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.